Market Performance - The North Exchange 50 Index saw a weekly increase of +0.58% from February 9 to February 13, 2026[3] - The average daily trading volume on the North Exchange was approximately CNY 18.575 billion, with a total trading volume of CNY 92.876 billion and a turnover rate of 16.85% during the same period[4][5] - The overall price-to-earnings (P/E) ratio for the North Exchange was approximately 46.94 times, which is higher than the ChiNext's 45.74 times but lower than the Sci-Tech Innovation Board's 78.61 times[21] Sector Performance - Among the 294 listed companies on the North Exchange, 103 companies had positive weekly growth, with the highest being Aide Technology (+144.72%) and Haiseng Medical (+133.86%)[10] - The media sector experienced a significant increase of +22.6%, while the oil and petrochemical sector saw a decline of -8.7%[10] Financing and Regulatory Measures - The North Exchange introduced a comprehensive package of measures to optimize refinancing, focusing on supporting quality listed companies and innovative small and medium-sized enterprises[40] - Key measures include improving the review process for quality companies, enhancing inclusivity for innovative SMEs, simplifying disclosure requirements, and strengthening regulatory oversight[41] Investment Strategy - The recommended investment strategy for 2026 emphasizes focusing on new productive forces in sectors such as renewable energy, intelligent manufacturing, and emerging consumption industries[27] - A bottom-up approach based on financial metrics is advised, targeting companies with high growth potential and strong R&D investment[27] Risk Factors - Potential risks include lower-than-expected policy support, rapid technological changes, and intensified market competition[3]

Core Insights - The A-share market has welcomed 16 new listings since 2026, with four medical device companies standing out as a highlight of the new year [1] - The newly listed medical device companies have shown impressive first-day performance, with all four stocks rising over 170% on their debut [1][3] - The strong stock performance is supported by positive earnings forecasts, with all four companies expected to report growth in 2025 [1][5] Group 1: Market Performance - The four medical device stocks, including Beixin Life, Haiseng Medical, Aide Technology, and Aishalen, experienced significant first-day gains, with Beixin Life rising by 183.33% on its debut [3] - As of February 13, the stock prices for these companies ranged from 18.77 yuan to 39.48 yuan, with total market capitalizations between 22.17 billion and 164.6 billion yuan [3] - The medical device sector is currently in a high-growth cycle, attracting significant capital market attention [7] Group 2: Company Performance and Projections - Beixin Life, which focuses on cardiovascular disease diagnostic devices, is projected to turn a profit in 2025, with expected revenues between 520 million and 560 million yuan, representing a growth of 64.24% to 76.88% [6] - Haiseng Medical anticipates a revenue of 345 million yuan in 2025, a year-on-year increase of 13.68%, while Aide Technology expects approximately 302 million yuan, up 9.74% [6] - Aishalen forecasts revenues between 890 million and 940 million yuan, with a growth rate of 28.65% to 35.89% due to increased demand and expanded production capacity [6] Group 3: Industry Trends and Future Prospects - The medical device IPO trend continues, with several companies, including Guangdong Boma Medical Technology, in the pipeline for listing [8] - Companies like Core Medical and Tongxin Medical are also vying to become the first domestic artificial heart stock, despite not yet being profitable [9] - The medical device sector is shifting from "concept speculation" to "performance-driven" investments, emphasizing the importance of technological originality and profitability [9]

Core Insights - Aide Technology (920180) was featured on the Dragon and Tiger List on February 13, 2026, due to a turnover rate of 21.49% and a trading volume of 5.71 million shares, amounting to a transaction value of 108 million yuan [1][2]. Trading Activity - The top buying seat was from GF Securities Co., Ltd. Urumqi Beijing Middle Road Branch, with a purchase amount of 2.13 million yuan [1][2]. - The top selling seat was from Guosen Securities Co., Ltd. Hubei Branch, with a selling amount of 6.46 million yuan [1][2]. - Other notable buying seats included: - China Merchants Securities Co., Ltd. Nanjing Zhongshan South Road Branch: 1.95 million yuan [2]. - Huatai Securities Co., Ltd. Shenzhen Shennan Avenue Branch: 1.81 million yuan [2]. - Other notable selling seats included: - Huatai Securities Co., Ltd. Chengdu Shujin Road Branch: 4.67 million yuan [2]. - Shenwan Hongyuan Securities Co., Ltd. Fuzhou Guping Road Branch: 1.99 million yuan [2].

证券代码：920180 证券简称：爱得科技 公告编号：2026-013 苏州爱得科技发展股份有限公司 关于签署募集资金三方及四方监管协议的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、募集资金基本情况 苏州爱得科技发展股份有限公司（以下简称"公司"）向不特定合格投资 者公开发行股票并在北京证券交易所上市申请已于2025年11月21日经北京证券 交易所上市委员会审议通过，并由中国证券监督管理委员会于2025年12月31日 出具《关于同意苏州爱得科技发展股份有限公司向不特定合格投资者公开发行 股票注册的批复》（证监许可〔2025〕3027号）同意注册，公司股票于2026年2 月10日在北京证券交易所上市。 公司本次向不特定合格投资者发行股票29,530,762股，每股发行价格为人 民币7.67元，募集资金总额为人民币226,500,944.54元，扣除不含税的发行费 用29,514,231.13元，募集资金净额为人民币196,986,713.41元，募集资金已于 2026年2月4日划至公司指定 ...

Core Viewpoint - On February 12, 2026, Aide Technology (920180) was featured on the trading leaderboard of the Beijing Stock Exchange due to a significant trading volume, with a turnover rate of 39.13% and a transaction amount of 204 million yuan [1]. Trading Activity Summary - The total trading volume for Aide Technology on this day reached 10.39 million shares, with a total transaction value of 204 million yuan [1]. - The top buying seat was Huatai Securities Co., Ltd. Chengdu Shujin Road Securities Business Department, which purchased approximately 6.08 million yuan worth of shares [2]. - The top selling seat was Dongwu Securities Co., Ltd. Wenzhou Chezhang Avenue Securities Business Department, which sold approximately 10.84 million yuan worth of shares [2].

Core Insights - The overall performance of the Beijing Stock Exchange (BSE) on February 11, 2026, showed a decline of 0.44% for the BSE 50 index, closing at 1,525.49 points, while the specialized and innovative index increased by 0.08% to 2,552.04 points [3][4] - The total market capitalization of the BSE reached 9,295.01 billion, with a circulating market value of 5,724.27 billion, indicating a decrease in trading activity compared to the previous week [3][4] - The average price-to-earnings (P/E) ratio for BSE-listed companies was reported at 47.24 times, which is higher than the P/E ratios of the STAR Market (77.90 times) and the ChiNext (45.77 times) [3][11] Market Performance - On February 11, 2026, the BSE recorded a total trading volume of 169.50 billion with 6.51 million shares traded, reflecting a decrease from the previous week's average daily trading volume of 204.84 billion [3][4] - The industry performance was mixed, with the top gainers being non-ferrous metals (1.2%), social services (1.0%), and textiles and apparel (0.5%), while the largest declines were seen in media (-5.7%), telecommunications (-2.0%), and food and beverage (-1.3%) [3][4] Stock Performance - Among the 293 listed companies on the BSE, 73 experienced an increase in stock price, 9 remained flat, and 211 saw a decline. The top gainers included Minshida (+8.44%), Gebijia (+8.05%), and Lingge Technology (+7.58%) [3][8] - Conversely, the largest declines were noted in Kaide Quartz (-7.40%), Optech (-6.05%), and Aide Technology (-5.75%) [3][9] Valuation Insights - The average P/E ratio for the non-ferrous metals sector was the highest at 124.4 times, followed by telecommunications at 91.9 times and food and beverage at 82.7 times [3][11] - The valuation of BSE-listed companies has shown a slight decrease compared to the previous trading day, indicating a potential shift in market sentiment [3][11]

Core Viewpoint - On February 11, 2026, Aide Technology (stock code: 920180) listed on the Beijing Stock Exchange experienced significant trading activity, with a turnover rate of 50.74% and a transaction volume of 13.4867 million shares, amounting to 275 million yuan [1]. Trading Activity - The trading method was continuous bidding, indicating high investor interest in the stock [1]. - The top buyer was Dongwu Securities Co., Ltd., Wenzhou Chezhang Avenue Securities Business Department, purchasing shares worth 11.6221 million yuan [1]. - The top seller was Great Wall Securities Co., Ltd., Shanghai Changning District Yan'an West Road Securities Business Department, selling shares worth 8.5383 million yuan [1].

Core Viewpoint - The successful listing of Suzhou Aide Technology Development Co., Ltd. on the Beijing Stock Exchange marks a significant milestone, providing new capital support for its future development and enhancing its market confidence in the orthopedic medical device sector [1][3][10]. Listing Overview - Aide Technology raised approximately 227 million yuan through its transfer to the Beijing Stock Exchange, with plans to invest in orthopedic consumables expansion, R&D center construction, and marketing network expansion [3]. - The company issued about 29.53 million shares at a price of 7.67 yuan per share, achieving a first-day opening increase of over 220%, closing at 21.23 yuan per share, a rise of 176.79%, with a trading volume of 553 million yuan and a turnover rate of 89.61% [3]. - The successful listing not only provides capital support for further development but also strengthens the company's market position and potential for business expansion [3]. Performance Overview - In 2025, Aide Technology reported a revenue of 302 million yuan, a year-on-year increase of 9.74%, and a net profit of 77.75 million yuan, up 15.82% year-on-year [4]. - The company's operating profitability is strong, with a non-recurring net profit growth of approximately 17.99%, indicating high profit quality [4]. - Despite facing market challenges in 2023, the company adjusted its strategy and enhanced product R&D, achieving steady recovery in 2024 and 2025, with a revenue and net profit growth of about 19.07% in the first half of 2025 [4]. Product Layout - Aide Technology has focused on the research, production, and sales of orthopedic medical devices since its establishment, achieving significant success in spinal minimally invasive intervention and trauma repair [5][7]. - The company has a strong technical advantage in the spinal minimally invasive intervention field, with its vertebroplasty system ranking among the top three in the domestic market [7]. - Aide Technology is expanding its product layout into trauma repair and sports medicine, continuously investing in R&D to enrich its product line and aiming to become a comprehensive solution provider in the orthopedic medical device sector [7]. Development History - Since its establishment in 2006, Aide Technology has undergone multiple technological innovations and market breakthroughs, evolving from a small-scale enterprise focused on imitating imported products to a leading company in the domestic orthopedic medical device industry [8][9]. - The company's development history reflects its deep accumulation in the orthopedic medical device field and its adaptability to changing market conditions [9]. Conclusion - The successful transfer to the Beijing Stock Exchange provides Aide Technology with broader capital market resources and injects new vitality into its future development [10]. - With ongoing capital support, the company is expected to enhance its brand influence and pursue higher-level development, anticipating broader growth opportunities in domestic and international markets as it expands its product line and improves its technology [10].

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase of over 15% compared to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 products across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 9327.94 million yuan, 6356.86 million yuan, 6713.05 million yuan, and 7775.27 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. Company Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium Enterprises" [3][28]. Competitive Advantages - The company has a well-established national sales network and a deep communication mechanism with hospitals and orthopedic doctors, enhancing product recognition and market penetration [5][35]. - Aide Technology has obtained 108 patents, with a research and development investment ratio of 6.96% from 2022 to 2024, indicating a strong commitment to innovation [5][35]. Market Trends - The demand for orthopedic implants is driven by a high prevalence of osteoporosis and vertebral compression fractures among the elderly population, with over 32% of individuals aged 65 and above affected [4][36]. - The company is adapting to the normalized procurement policies by promoting non-procurement products, which have shown steady growth, partially offsetting the revenue decline from procurement products [47]. Valuation Analysis - The company's projected price-to-earnings (PE) ratio for 2024 is 13.50, which is at a discount compared to comparable companies in the industry, whose average PE is 57.78 [25][26].

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase exceeding 15% relative to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 items across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 93.28 million yuan, 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. - The company's gross margin is expected to be 62.45%, 57.80%, 58.05%, and 58.90% from 2022 to 2025 [50]. Business Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium-sized Enterprises" [3][28]. Competitive Position - The company ranks third among domestic manufacturers of spinal vertebral body shaping systems and sixth among spinal implant manufacturers [3][28]. - Aide Technology has a well-established national sales network and a strong communication mechanism with hospitals and orthopedic surgeons, enhancing product recognition and market penetration [5][35]. Investment Analysis - The company is positioned to benefit from the ongoing trend of centralized procurement in the industry, which is expected to normalize pricing and enhance market opportunities [4][36]. - The company’s revenue from non-procurement products is growing, helping to offset declines in procurement product revenues [47]. Use of Proceeds - The company plans to use the proceeds from its public offering for expanding orthopedic consumables production, building a research center, and enhancing its marketing network [53][54].